- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03659825
Ketone Esters for Optimization of Cognitive Performance in Hypoxia
Study Overview
Status
Intervention / Treatment
Detailed Description
In the setting of altitude-induced hypoxia, cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have shown that the presence of elevated ketone bodies (ketosis) maintains brain ATP levels and reduce cerebral anaerobic glycolysis during hypoxia. Ketosis can be achieved when fasting or following a ketogenic diet; however, these approaches are impractical. Exogenous ketone ester supplementation allows for rapid (< 30 mins) and significant elevation of blood ketone levels without the need to maintain a diet or fast.
HVMN, in collaboration with researchers at IHMC, proposes a study to investigate the effects of consuming an FDA-approved ketone ester 'food' on cognitive performance in the setting of hypoxia. For the proposed 4-arm within-subject study, participants will complete a cognitive performance test battery under the conditions of normoxia and then hypoxia following consumption of a ketone ester drink or a placebo drink (N.B for each study drink cognitive performance in both hypoxia and normoxia will be assessed in ONE visit):
VISIT A:
Arm1: Normoxia + Placebo Arm 2: Hypoxia + Placebo
VISIT B:
Arm 3: Normoxia + Ketone ester Arm 4: Hypoxia + Ketone ester
The investigators hypothesize that ketone ester supplementation will attenuate hypoxia-induced deterioration of operator cognitive performance.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
* Pass medical examination on enrollment.
Exclusion Criteria:
* Active smoker, substance abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo + Normoxia
Taste, volume and appearance matched drink given before cognitive testing in normoxia
|
Placebo that tastes similar to active intervention
|
|
Placebo Comparator: Placebo + Hypoxia
Taste, volume and appearance matched drink given before cognitive testing in hypoxia
|
Placebo that tastes similar to active intervention
Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
|
|
Experimental: Ketone Ester + Normoxia
Ketone ester drink given before cognitive testing in normoxia
|
Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
Other Names:
|
|
Experimental: Ketone Ester + Hypoxia
Ketone ester drink given before cognitive testing in hypoxia
|
Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cognitive Performance- Visual Acuity
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (visual acuity) will be assessed using the RightEye testing system (https://www.righteye.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
|
Change in Cognitive Performance- Contrast Sensitivity
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (contrast sensitivity) will be assessed using the RightEye testing system (https://www.righteye.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
|
Change in Cognitive Performance- Choice Reaction Time
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (choice reaction time) will be assessed using both the RightEye testing system (https://www.righteye.com)
and the DANA testing system (http://www.danabrainvital.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
|
Change in Cognitive Performance- Eye Tracking- Smooth Pursuit
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (eye tracking) will be assessed by looking for smooth pursuit (horizontal and vertical) using the RightEye testing system (https://www.righteye.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
|
Change in Cognitive Performance- Eye Tracking- Saccades
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (eye tracking) will be assessed by looking at saccade speed (horizontal and vertical) using the RightEye testing system (https://www.righteye.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
|
Change in Cognitive Performance- Simple Reaction Time
Time Frame: Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Cognitive performance (simple reaction time) will be assessed using both the RightEye testing system (https://www.righteye.com)
and the DANA testing system (http://www.danabrainvital.com).
|
Measured 3 times (baseline [time = 0 min], during normoxia [time = 30-60 min post study drink 1] and during hypoxia [30-60 min post study drink 2]) in each of the two test visits.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Grip Strength
Time Frame: Measured 3 times (baseline [time = 0 min], after normoxia [60 min post study drink 1] and after hypoxia [60 min post study drink 2]) in each of the two test visits.
|
Grip strength will be measured using a
|
Measured 3 times (baseline [time = 0 min], after normoxia [60 min post study drink 1] and after hypoxia [60 min post study drink 2]) in each of the two test visits.
|
|
Change in blood ketone levels
Time Frame: Measured 5 times at regular intervals through each of the two study visits. [time (min) = 0, 30, 75, 105, 150]
|
Blood ketone levels will be measured in a finger prick blood samples using a clinical grade, handheld glucose/ketone meter (Abott Diabetes Care).
|
Measured 5 times at regular intervals through each of the two study visits. [time (min) = 0, 30, 75, 105, 150]
|
|
Change in blood glucose levels
Time Frame: Measured 5 times at regular intervals through each of the two study visits. [time (min) = 0, 30, 75, 105, 150]
|
Blood glucose levels will be measured in a finger prick blood samples using a clinical grade, handheld glucose/ketone meter (Abott Diabetes Care).
|
Measured 5 times at regular intervals through each of the two study visits. [time (min) = 0, 30, 75, 105, 150]
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, Magor-Elliott S, Hiyama S, Stirling M, Clarke K. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017 Oct 30;8:848. doi: 10.3389/fphys.2017.00848. eCollection 2017.
- Suzuki M, Suzuki M, Sato K, Dohi S, Sato T, Matsuura A, Hiraide A. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001 Oct;87(2):143-50. doi: 10.1254/jjp.87.143.
- Kirsch JR, D'Alecy LG, Mongroo PB. Butanediol induced ketosis increases tolerance to hypoxia in the mouse. Stroke. 1980 Sep-Oct;11(5):506-13. doi: 10.1161/01.str.11.5.506.
- Xu K, Sun X, Eroku BO, Tsipis CP, Puchowicz MA, LaManna JC. Diet-induced ketosis improves cognitive performance in aged rats. Adv Exp Med Biol. 2010;662:71-5. doi: 10.1007/978-1-4419-1241-1_9.
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEHYPOX18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxia
-
Direction Centrale du Service de Santé des ArméesNot yet recruitingHypoxia | Hypoxia, Brain | Hypoxia in Healthy Individuals | Hypoxia, Altitude | Altitude Hypoxia | Altitude | Hypoxia Altitude Simulation Test | Hypoxia Brain | Normobaric HypoxiaFrance
-
Universite du Littoral Cote d'OpaleNot yet recruitingNormoxia | Intermittent Moderate Hypoxia | Continuous Moderate HypoxiaFrance
-
Western University, CanadaCompletedBrain Hypoxia IschemiaCanada
-
Jorge Torres MejíasEnrolling by invitationChanges in the Intestinal Microbiota Under Hypobaric Hypoxia Conditions | Changes in Blood Glucose Under Hypobaric Hypoxia Conditions | Changes in Body Composition Under Hypobaric Hypoxia Conditions | Determination of Physiological Stress in Hypobaric HypoxiaChile
-
Yale UniversityTianjin Chest HospitalCompletedBrain Ischemia Hypoxia | Muscle; Ischemic | Muscle HypoxiaChina
-
Fliegerärztliches InstitutCompleted
-
University of Texas at AustinCompletedIntermittent HypoxiaUnited States
-
Owlet Baby Care, Inc.Completed
-
Robert L. OwensCompletedIntermittent HypoxiaUnited States
-
Montreal Heart InstituteUniversité de MontréalCompleted
Clinical Trials on Taste Matched Placebo
-
Jason Allen, Ph.D.TerminatedHeart FailureUnited States
-
University Medical Center GroningenNetherlands Heart FoundationCompletedHeart Failure | Heart Failure With Reduced Ejection FractionNetherlands
-
Anglia Ruskin UniversityFattoria La Vialla di Gianni, Antonio e Bandino Lo Franco Soc. Agr. Sempl.Completed
-
Bournemouth UniversityEnrolling by invitationDietary Behavior | Free Sugar | Sweet TasteUnited Kingdom
-
Beijing Supreme Life Pharmaceutical Technology...Peking University People's HospitalRecruitingDiabetes Mellitus, Type 2 | Diabetes | Type2diabetesChina
-
Penn State UniversityCompletedBehavior, HealthUnited States
-
Wake Forest University Health SciencesRecruiting
-
Yağmur MalkocIstanbul Medipol University HospitalCompleted
-
Novo Nordisk A/SNot yet recruitingObesity | Diabetes Mellitus, Type 2 | OverweightIndia, Thailand, United States, Poland, Germany, Croatia, Hungary, Romania, Argentina, Mexico, Portugal, Bulgaria, Brazil, Turkey (Türkiye)
-
Centre Hospitalier Universitaire DijonRecruitingUnder-consumption of FoodFrance